Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NIH Conflict Of Interest Reg Aims To Bolster Public Trust As Links To Industry Flourish

This article was originally published in The Pink Sheet Daily

Executive Summary

Upgrade of the 1995 regs is "an insurance plan" against potential trouble downstream, NIH Director Collins says, but some advocacy groups wanted broader disclosure.

You may also be interested in...

NIH Conflict Of Interest Database Causing Fight At White House OMB

A government watchdog group is worried that the White House Office of Management and Budget is about to take the teeth out of the National Institute of Health's proposed new conflict of interest rule.

NIH Translational Center To Study Cell-Based Toxicity Tests, Offer Industry Grants

Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.

UCSF Chancellor Desmond-Hellmann Talks Academic Partnerships

At Bio-Windhover's Pharmaceutical Strategic Outlook conference, Susan Desmond-Hellmann discussed UCSF's evolving relationships with big pharma.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts